Peptide education
MOTS-c
Mitochondrial open reading frame of the 12S rRNA-c
MOTS-c is a 16-amino-acid peptide encoded in the DNA of the mitochondrion itself, one of a small family of peptides that organelle is known to produce. In cells and rodents it behaves like a stress signal: it activates AMPK, moves into the nucleus when metabolism is under pressure, and changes how muscle and glucose are handled. That much is documented. What is not documented is what happens when you inject it into a person, because no outcome trial of administered MOTS-c has been published. The human record so far is two studies that measured the MOTS-c people already carry, plus one treatment trial that is still recruiting.
Every human MOTS-c source so far either measured the peptide your body already makes or registered a trial that has not reported. The fat-loss, endurance, energy, and longevity claims come from mice, cells, and the market.
Overview
Quick answer
Measuring endogenous MOTS-c in blood or tissue is different from giving MOTS-c to a person. A vial sold as MOTS-c also needs its own identity, sterility, stability, and dosing evidence before it can be compared with controlled investigational material.
What is it?
MOTS-c is short for mitochondrial open reading frame of the 12S rRNA type-c: a 16-amino-acid peptide made from the mitochondrial genome, not the nuclear one. Researchers treat it as a signal linking mitochondrial stress to whole-body metabolism.
Why is it discussed?
Because the rodent data are unusually good. MOTS-c improved metabolism and insulin sensitivity in mouse models and picked up an exercise-mimetic reputation from the preclinical work. Sellers converted that animal record into human promises without waiting for a human result.
What has been shown in humans?
Association, not treatment. One study found plasma MOTS-c tracks with insulin-sensitivity measures; another measured circulating MOTS-c in metformin-treated breast-cancer patients. The one actual treatment trial, a phase 2a study in adults with prediabetes and overweight or obesity, is still recruiting and has posted no results.
What route and schedule have actually been studied?
The registered MOTS-MET trial gives subcutaneous MOTS-c or placebo at a fixed dose once daily for 12 weeks, with safety follow-up through week 16. That is a trial protocol, and it is the only concrete human schedule in the public record.
What do clinics and online sellers add?
Energy, endurance, fat loss, insulin support, longevity, and routines of about 5 mg two or three times a week. None of that comes from a completed human study; it is community convention extrapolated from animal doses.
How strong is the evidence?
Strong enough to justify the phase 2 trial now recruiting, too weak to justify the way it is sold. Biomarker associations, mouse experiments, and a vendor vial are three different kinds of evidence, and only the first two exist.
Reported practice
Commonly reported protocol
Community metabolic protocols. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
Human sources measure circulating or plasma MOTS-c in metabolic contexts. They can support discussion of association and biomarker interest. They are not the same as an administered MOTS-c outcome trial.
ClinicalTrials.gov lists a randomized, double-blind, placebo-controlled MOTS-c study in adults with prediabetes and overweight or obesity. It gives route, design, and endpoints, but no efficacy claim before results are posted.
The strongest papers discuss metabolic homeostasis, nuclear translocation during metabolic stress, plasma metabolites, and insulin-sensitivity biology. That makes MOTS-c plausible to study, but it does not yet make MOTS-c a demonstrated human longevity or metabolic treatment.
Longevity, energy, endurance, and body-composition claims mostly borrow from mitochondrial mechanism, animal work, and online discussion. The available human sources do not include those outcomes.
A label or purity claim on a research-market product does not answer identity, assay, sterility, endotoxin, concentration, stability, storage, or chain-of-custody questions.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| MOTS-c improves insulin sensitivity. | Human sources currently support biomarker and association language. One plasma study links MOTS-c levels with insulin-sensitivity context, and a phase 2a trial is designed to test insulin sensitivity in adults with prediabetes and overweight or obesity, but intervention outcomes have not been posted. | Preclinical and mechanism sources make the claim biologically plausible through metabolic homeostasis, AMPK-related signaling, and stress-response gene regulation. | Market and community discussion often treats insulin-sensitivity support as already practical. The cited human sources do not include controlled outcomes for that practical claim. | Worth following, but the key missing evidence is still a posted human outcome from administered MOTS-c. |
| MOTS-c supports weight loss or body recomposition. | The human MOTS-c material here does not include completed weight-loss or body-composition outcomes after MOTS-c administration. The recruiting phase 2a study includes cardiometabolic endpoints, but no results are posted. | Preclinical metabolic-homeostasis work explains why weight and substrate metabolism are discussed, but animal and mechanism data do not settle human fat-loss claims. | Gray-market and clinic-style discussion often presents MOTS-c as a metabolic or body-composition peptide. That shows how it is marketed, not that it produces those outcomes. | MOTS-c remains a metabolic research peptide. Human weight-loss and body-recomposition outcomes have not been shown. |
| MOTS-c is a longevity or anti-aging peptide. | Human lifespan, healthspan, frailty, or aging-outcome intervention evidence has not been found for administered MOTS-c. | Mitochondrial stress signaling and metabolic homeostasis make MOTS-c relevant to aging research discussions. That relevance is not the same as a demonstrated human longevity effect. | Longevity and "mitochondrial optimization" language appears in public discussion, but it remains anecdotal or market-reported unless direct evidence is added. | Longevity is a real public claim around MOTS-c, but it has not been shown as a human benefit. |
| MOTS-c improves energy, endurance, or exercise adaptation. | The cited human sources do not include evidence that administered MOTS-c improves energy, endurance, fatigue, or exercise performance. | A mitochondrial-derived peptide connected to metabolic stress and skeletal-muscle signaling is a plausible exercise-adaptation research target, but plausibility does not create a route, amount, or outcome standard. | Energy and endurance are common public discussion topics around mitochondrial peptides. The MOTS-c material here does not provide controlled human evidence strong enough to promote those claims. | For now, this is market and anecdotal discussion unless direct human intervention data become available. |
| Subcutaneous MOTS-c has a standard public schedule. | The registry describes a subcutaneous, fixed-dose, once-daily, 12-week study pattern with follow-up through week 16. It does not provide a public-use recommendation, real-world amount, or posted efficacy results. | Mechanism cannot determine the right amount, schedule, duration, or safety monitoring plan for off-trial use. | Clinic, vendor, and community discussion points to protocol interest, but it does not provide a reliable real-world schedule, amount, route instruction, stacking pattern, reconstitution detail, or personal protocol. | The concrete schedule here is the trial-registry pattern. Public schedules outside that trial still need direct support. |
| A research-use MOTS-c vial is equivalent to investigational study material. | Human biomarker papers and a trial registry do not verify the identity or quality of products sold online. | The issue is not mitochondrial theory. It is an identity, sterility, endotoxin, impurity, assay, stability, and chain-of-custody question. | Product pages, COAs, and community reports can create confidence, but they do not substitute for controlled manufacturing and release documentation. | No. Product quality has to be checked separately from the molecule's research rationale. |
Bottom line
Main takeaway
MOTS-c is a genuine mitochondrial peptide with impressive animal data behind it, and not one published human outcome. Those two facts have to travel together.
Split the record into three piles: human biomarker associations, preclinical mechanism, and a recruiting trial with no results. The market prices MOTS-c as if the third pile were already filled in.
Start with the 2015 metabolic-homeostasis paper, the nuclear-translocation and insulin-sensitivity work, the plasma-metabolite study, and the NCT07505745 registry entry. Nothing administered to humans has been published beyond what that registry describes.
Identity
What it is
MOTS-c is a small peptide encoded in the 12S rRNA region of mitochondrial DNA: 16 amino acids made by the organelle rather than the nucleus. Its best-studied job is metabolic signaling, through AMPK activation tied to folate-purine metabolism.
Under metabolic stress, MOTS-c can leave the mitochondria, enter the nucleus, and interact with stress-response genes. Rodent studies built on that finding produced the reputation: better glucose handling, resistance to diet-induced obesity, exercise-mimetic effects. That reputation is what the peptide market sells.
The missing chapter is the human one. Researchers have measured MOTS-c in people's blood and found it tracks with insulin sensitivity and metabolic state, but measuring a peptide and injecting it are different experiments. A registered phase 2a trial in adults with prediabetes is now asking the injection question properly. Until it reports, every vial sold is ahead of the evidence.
How people talk about it online
Online, MOTS-c is sold as an exercise-mimetic: fat loss, endurance, energy, insulin support, and healthy aging, often timed as a pre-workout injection. That framing comes straight from the rodent literature, where effects like those were actually measured.
The common community schedule, about 5 mg two or three times a week or 5 to 10 mg weekly for 4 to 8 weeks, has no human study behind it. It is convention that hardened into protocol.
Clinic and vendor pages also stack MOTS-c next to NAD+, which is a separate compound with its own thin human record. Two plausible mechanisms do not add up to one demonstrated benefit.
Every MOTS-c vial sold online is research-market material: no approved product exists, and a purity percentage on a website does not answer the sterility, identity, or dosing questions that even the clinical trial is still working through.
Use context
Routes, doses, and cycle patterns
The registered investigational study uses subcutaneous MOTS-c or placebo, a fixed once-daily schedule, and defined follow-up. Market claims instead center on energy, metabolism, body composition, and longevity without providing a dependable public amount, cycle, or product standard.
Human studies and product labels
MOTS-MET phase 2a registry pattern
- Purpose
- Insulin-sensitivity and cardiometabolic-risk research in adults with prediabetes and overweight or obesity
- Context
- Randomized, double-blind, placebo-controlled phase 2a registry listing
- Route
- Subcutaneous injection
- Amount
- Fixed dose; no real-world amount is provided
- Frequency
- Once daily in the study context
- Duration
- 12-week treatment period with safety follow-up through week 16
This is the schedule for a recruiting trial. It shows what is being tested, not a public regimen.
Human biomarker studies
- Purpose
- Circulating or plasma MOTS-c levels in metabolic contexts
- Context
- Human association and circulating-level research
- Route
- No administered MOTS-c route
- Amount
- Endogenous biomarker context; no administered MOTS-c amount
- Frequency
- Endogenous biomarker context; no administered MOTS-c frequency
- Duration
- Study-specific sampling, not a treatment cycle
These studies help explain metabolic interest in MOTS-c, but they do not give route, amount, frequency, duration, or cycle guidance for administered peptide use.
Real-world discussion
Community metabolic protocols
- Purpose
- Metabolic health, exercise capacity, and fat-loss discussion
- Context
- Clinics, forums, and vendor listings
- Route
- Subcutaneous injection
- Amount
- The common community pattern is 5 mg per injection two to three times per week, often timed before exercise, or 5 to 10 mg once weekly.
- Frequency
- Once weekly to three times weekly in most descriptions
- Duration
- Most often 4 to 8 week runs
MOTS-c is a mitochondrial-derived peptide with compelling rodent metabolic data and no controlled human outcome data, so these schedules are community convention extrapolated from animal work. Reported as context, not a recommendation.
What varies
- Evidence setting: biomarker studies explain association, mechanism papers explain plausibility, the trial registry shows what is being tested, regulator documents flag product risk, and market discussion shows interest.
- Route: the registered intervention trial is subcutaneous; that tells you the research route, not whether an online vial is sterile, stable, correctly filled, or clinically useful.
- Amount: no real-world amount is supported here; the registry pattern is fixed-dose study context.
- Frequency and duration: once daily for 12 weeks is the trial pattern, with safety follow-up through week 16.
- Product quality: identity, assay, impurities, sterility, endotoxin, concentration, stability, storage, and chain of custody matter before any vial claim is taken seriously.
Human data
Human evidence
In humans, MOTS-c has been observed, not tested. A plasma study linked circulating MOTS-c to insulin-sensitivity measures, and a second study measured it in metformin-treated breast-cancer patients; both are association data. The only intervention on record is MOTS-MET, a randomized, double-blind, placebo-controlled phase 2a trial in adults with prediabetes and overweight or obesity, and it is still recruiting. Its endpoints are OGTT-derived insulin sensitivity, treatment-emergent adverse events, glucose measures, and immunogenicity. Until results post, the strongest honest statement is that the human experiment is underway.
Evidence maturity
MOTS-c has moved from mechanism and biomarker interest into registered human testing, but no posted human outcome results were found.
Metabolic homeostasis, stress-response gene regulation, and metabolite sources.
Plasma and circulating-level studies justify association language.
Recruiting study with a subcutaneous once-daily treatment pattern and no posted results.
Marketed products need their own identity and quality evidence.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Plasma MOTS-c and insulin sensitivity | Lean and obese individuals in a human biomarker association study | Human plasma association research | Endogenous biomarker measurement, not administered MOTS-c | A human biomarker study measured plasma MOTS-c alongside insulin-sensitivity measures. It supports association language, not claims that administered MOTS-c improves insulin sensitivity. | Association studies are useful for biology, but they do not answer whether giving MOTS-c changes insulin sensitivity, weight, endurance, or longevity. | Limited human biomarker evidence |
| Circulating MOTS-c in metformin-treated breast-cancer context | Patients with breast cancer treated with metformin in a circulating-level study | Human circulating-level source | Endogenous circulating-level context, not a MOTS-c treatment trial | This disease-context study measured circulating MOTS-c in a metformin-treated breast-cancer setting, so it is useful background for metabolic signaling but not evidence for MOTS-c treatment. | Disease context, metformin context, and circulating levels are too indirect for MOTS-c efficacy claims. | Limited adjacent human evidence |
| MOTS-MET phase 2a registry | Adults with prediabetes and overweight or obesity | Randomized, double-blind, placebo-controlled phase 2a trial registration | Investigational MOTS-c under clinical-study conditions | The study is designed to evaluate OGTT-derived insulin sensitivity and treatment-emergent adverse events, with secondary glucose and immunogenicity endpoints. | Recruiting trial; no posted outcome results are used as outcome evidence. | Trial tracking; no outcomes yet |
| Metabolic mechanism and plasma-metabolite sources | Model systems and translational/metabolite context | Preclinical and mechanism research | Mechanism and plausibility sources, not approved product data | Supports metabolic plausibility, stress-response biology, and insulin-sensitivity research rationale. | Species differences, dose conversion, route safety, and product quality still have to be answered before real-world claims carry much weight. | Preclinical or mechanism evidence |
Use context
Reported use context
Route and schedule details come from the trial registry, not from a settled public regimen. Clinic and community claims show interest in energy, metabolism, body composition, and longevity, but they do not provide a consistent amount, schedule, or cycle.
Study and label context
Fixed-dose once daily treatment for 12 weeks, with safety follow-up through week 16. This is a trial schedule only; it does not give an amount, product, source, or personal-use instruction.
MOTS-c was measured as endogenous circulating or plasma MOTS-c rather than administered as a treatment. These papers are useful for biomarker interpretation, not route, amount, frequency, duration, or cycle guidance.
Real-world discussion
The common community pattern is 5 mg per injection two to three times per week, frequently timed before exercise, or 5 to 10 mg once weekly, in cycles of about 4 to 8 weeks. These are anecdotal and market-reported ranges; no controlled human dosing study confirms them.
Cautions
Safety and unknowns
- The main human safety gap is simple: biomarker studies do not answer administered-MOTS-c tolerability, dose-response, adverse-event rates, or long-term safety.
- The phase 2a registry includes treatment-emergent adverse events and immunogenicity as safety-related endpoints, but posted results are not available.
- Mechanism and animal work do not settle injection-site reactions, immunogenicity, contamination, sterility, endotoxin, impurity, or repeated exposure risk for products sold outside controlled research.
- Metabolic populations can have glucose, weight, cardiovascular, kidney, and medication variables that make casual extrapolation especially weak.
Product quality
A vial label is only a starting point
MOTS-c product quality is not the same thing as MOTS-c biology. A peptide can have a plausible mechanism while a particular vial still needs identity, concentration, sterility, stability, and impurity documentation.
Research-use labels, vendor COAs, and purity percentages cannot show whether the vial matches investigational clinical-study material, was handled under sterile controls, or has route-specific human safety support.
Identity
Identity evidence establishes whether the material is MOTS-c, not just labeled as MOTS-c.
Assay and impurities
Percent purity can miss method quality, impurity profile, degradation, and whether the tested sample represents the actual lot.
Sterility and endotoxin
Injectable discussion creates contamination questions that a sequence name or HPLC claim does not answer.
Concentration and fill
Even correct identity does not answer the amount in the vial or the concentration after handling.
Stability and storage
Peptide degradation can be affected by manufacturing, shipping, storage, and handling conditions.
Regulatory context
Investigational or research-use context is not the same as an approved, labeled, quality-controlled medicine.
Mechanism
How it is proposed to work
MOTS-c is proposed to act as a mitochondrial-to-nuclear stress signal tied to metabolic homeostasis. In plain terms, researchers are asking whether a small peptide encoded by mitochondrial DNA can help coordinate how cells respond to nutrient and energy stress.
The metabolic-homeostasis source supports the basic research rationale: MOTS-c is linked to obesity and insulin-resistance models, energy handling, and insulin-sensitivity biology.
The nuclear-translocation source is important because it describes MOTS-c as a signal that can move into the nucleus and influence gene expression during metabolic stress.
The plasma-metabolite source supports a metabolite and insulin-sensitivity research line, but the interpretation still depends on design, species, population, and whether the study measured endogenous levels or administered compound.
This is the unresolved step across mitochondrial peptides: mechanism can guide what to test, but human benefit still needs human endpoint data.
FAQ
Common questions
Does MOTS-c work in humans?
Not yet shown. The compelling data — improved insulin sensitivity, exercise capacity, metabolic homeostasis — are rodent studies. Human trials are registered and underway, but no controlled human outcome results have been posted.
What doses do people report?
Community protocols commonly describe 5 mg per injection two to three times per week, or 5 to 10 mg once weekly, often timed before exercise, in 4 to 8 week runs. These are extrapolations from animal work.
Is MOTS-c on the FDA radar?
Yes. On July 23, 2026 the Pharmacy Compounding Advisory Committee voted 7-5 with two abstentions to recommend MOTS-c bulk substances for the 503A Bulks List, with obesity and osteoporosis as the uses evaluated. The recommendation is non-binding: it is not FDA approval or a safety finding, and compounding status stays unchanged until FDA completes formal rulemaking.
Details
Technical details
Sources
References
- 1.
FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee 2026.
Accessed 2026-07-24.
FDA meeting page for the July 23-24, 2026 PCAC review of BPC-157, KPV, TB-500, MOTs-C, emideltide/DSIP, Semax, and Epitalon bulk substances, including the uses evaluated for each, briefing documents, and docket FDA-2025-N-6895.
- 2.
FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks 2026.
Accessed 2026-06-08.
FDA summarizes potential significant safety risks and missing safety information for several nominated peptide bulk substances.
- 3.
PubMed. Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals 2018.
PMID:29593067 Accessed 2026-06-08.
Human biomarker association source; not an intervention trial.
- 4.
PubMed. Circulating levels of MOTS-c in patients with breast cancer treated with metformin 2022.
PMID:36490309 Accessed 2026-06-08.
Human circulating-level source; adjacent to metabolic signaling rather than an efficacy result.
- 5.
PubMed. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance 2015.
PMID:25738459 Accessed 2026-06-08.
Preclinical/metabolic mechanism source.
- 6.
PMID:29983246 Accessed 2026-06-08.
Mechanism source for nuclear translocation and stress response.
- 7.
PubMed. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity 2019.
PMID:31293078 Accessed 2026-06-08.
Metabolite/insulin-sensitivity source; interpret by design and species context.
- 8.
ClinicalTrials.gov. ClinicalTrials.gov record NCT07505745 2026.
NCT07505745 Accessed 2026-06-08.
Recruiting/no posted-results trial record at the 2026-06-08 source check.